Key result
Fresh decellularized pulmonary allografts link to longer reintervention-free survival over aortic and venous allografts.
Why the study?
The study aimed to compare the outcomes of different types of fresh decellularized allografts used for pulmonary valve replacement.
Does pulmonary valve replacement with fresh decellularized pulmonary allografts improve freedom from reintervention compared to aortic or venous allografts in patients with congenital heart disease?
Cohort (n=134)
No
Does pulmonary valve replacement with fresh decellularized pulmonary allografts improve freedom from reintervention compared to aortic or venous allografts in patients with congenital heart disease?
Fresh decellularized pulmonary allografts provide superior long-term durability compared to aortic and venous allografts for pulmonary valve replacement in congenital heart disease, whereas venous allografts exhibit rapid failure within the first year.
Answers are grounded in this paper and cite their sources.
Pulmonary allografts were associated with longer durability in this cohort; leaves open randomized confirmation before guiding conduit choice in congenital heart disease.
The OBJECTIVE was to perform a comparative analysis of the outcomes of using different types of fresh decellularized allografts in the pulmonary position.METHODS AND MATERIALS. The study was conducted at the Department of Surgery with the course of Cardiovascular Surgery of the Institute of Continuing Professional Education, Samara State Medical University, based at the V. P. Polyakov Samara Regional Clinical Cardiology Dispensary. This was a single-center retrospective comparative cohort study based on the experience of pulmonary valve replacement with fresh decellularized allografts in patients with congenital heart disease from 2008 to 2022. A total of 134 patients (72 males and 62 females) who met the inclusion criteria underwent 185 interventions on the pulmonary valve. Freedom from reintervention was assessed using the Kaplan–Meier method; intergroup differences were evaluated with the Mantel – Cox log-rank test. Statistical significance was set at p≤0.05.RESULTS. In the early postoperative period, all groups demonstrated a low rate of complications and 30-day mortality. During follow-up, redo valve replacement due to allograft dysfunction was required in 22 cases (11.9 %). Pulmonary allografts showed the best durability: the median freedom from reintervention was 156 months, compared with 95 months for aortic allografts and 10 months for venous allografts; the differences between the groups were statistically significant (p<0.001). Venous allografts were characterized by early calcification and a high need for reoperation during the first year of follow-up. In our cohort, older age at the time of surgery and larger conduit diameter were associated with longer allograft durability.CONCLUSION. Fresh decellularized pulmonary allografts demonstrated the best freedom from reintervention compared with aortic and, particularly, venous allografts and may be considered a preferred option for pulmonary valve replacement. Venous allografts in the pulmonary position were characterized by early dysfunction and a high need for reinterventions, which restricts their use as long-term valved conduits.
No takes yet. Share an insight, caveat, or question.
Svechkov et al. (2026) conducted a cohort in Congenital heart disease requiring pulmonary valve replacement (n=134). Fresh decellularized pulmonary allografts vs. Fresh decellularized aortic and venous allografts was evaluated on Freedom from reintervention (p=<0.001). Fresh decellularized pulmonary allografts achieved longer median freedom from reintervention (156 months) than aortic (95 months) and venous allografts (10 months; p<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: